Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug 28:4:79-81.
doi: 10.1016/j.ebcr.2015.07.004. eCollection 2015.

Levetiracetam-induced rage and suicidality: Two case reports and review of literature

Affiliations

Levetiracetam-induced rage and suicidality: Two case reports and review of literature

Orakwue A Molokwu et al. Epilepsy Behav Case Rep. .

Abstract

Background: Levetiracetam-induced rage is a rare neurobehavioral adverse effect of levetiracetam that is characterized by seething rage, uncontrollable anger, fits of fury, depression, violence, and suicidal tendencies. It occurs more in patients with prior mood or psychotic disturbances. No such case has been reported in Nigeria.

Method: We report two cases of levetiracetam-induced rage. The first patient was a 29-year-old male with a 14-year history of intractable posttraumatic epilepsy. He was initially placed on sodium valproate and phenobarbitone and later had phenobarbitone replaced with levetiracetam. Within the first week of initiating levetiracetam, he became aggressive, bursted into fits of fury, and attacked his siblings. Levetiracetam was stopped, and the seething rage ceased only to reappear when it was reintroduced; hence, the complete withdrawal of levetiracetam. Naranjo probability score for adverse drug reaction was 8.

Results: The second patient was a 23-year-old lady who developed seething rage and made several attempts to kill herself with a knife following addition of levetiracetam to the clonazepam and carbamazepine that she was taking for treatment-resistant epilepsy. Withdrawal and reintroduction of levetiracetam by the relatives led to cessation and reemergence, respectively, of the rage and suicidal tendencies. Naranjo score was 8. Levetiracetam was discontinued.

Conclusion: Neuropsychiatric evaluation for prior mood or psychiatric disorders in those initiating levetiracetam therapy is suggested alongside monitoring for early features of levetiracetam-induced rage by both caregivers and physicians. This will help stem the morbidity and potential mortality associated with this life-threatening adverse drug reaction.

Keywords: Adverse drug reaction; Antiepileptic drug; Kepprage; Levetiracetam-induced rage; Southeast Nigeria; Suicidality.

PubMed Disclaimer

References

    1. Commission on Epidemiology and Prognosis Guidelines for epidemiologic studies on epilepsy. Epilepsia. 1993;34(4):592–596. - PubMed
    1. Ngugi A.K., Bottomley C., Kleinschmidt I., Sander J.W., Newton C.R. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia. 2010;51:883–890. - PMC - PubMed
    1. Lhatoo S.D., Johnson A.L., Goodridge D.M., MacDonald B.J., Sander J.W., Shorvon S.D. Mortality in epilepsy in the first 11 to 14 years after diagnosis: multivariate analysis of long-term, prospective, population-based cohort. Ann Neurol. 2001;49:336–344. - PubMed
    1. LaRoche S.M., Helmers S.I. The new antiepileptic drugs. JAMA. 2004;291:605–614. - PubMed
    1. http://epilepsytalk.com/2010/10/15/keppra-%E2%80%93-what-people-are-sayi... [Last accessed 3rd April, 2014].